Acute coronary syndromes
KEYWORDS: people, coronary, acute, pci, risk, acute coronary, therapy, recommendations, committee, evidence, angina, unstable, nstemi, unstable angina, offer

who have had MI treatment with the following drugs: • angiotensin-converting enzyme (ACE) inhibitor • dual antiplatelet therapy (aspirin plus a second antiplatelet) unless they have a separate indication for anticoagulation (see the section on antiplatelet therapy for people with an ongoing separate indication for anticoagulation) • beta-blocker • statin. [2007, amended 2020] 1.4.2 Ensure that a clear management plan is available to the person who has had an MI and is also sent to the GP, including: • details and timing of any further drug titration • monitoring of blood pressure • monitoring of renal function. [2013] 1.4.3 Offer all people who have had an MI an assessment of bleeding risk at their follow-up appointment. [2013] 1.4.4 Rivaroxaban, with aspirin and clopidogrel, or aspirin alone, is recommended as an option in NICE technology appraisal guidance for preventing atherothrombotic Acute coronary syndromes (NG185) events in people who have had an acute coronary syndrome with elevated cardiac biomarkers, taking bleeding risk into account. For full details, see the guidance on rivaroxaban (TA335, 2015). 1.4.5 Rivaroxaban plus aspirin is recommended as an option in NICE technology appraisal guidance for preventing atherothrombotic events in some people with coronary artery disease who are at
